GlassScriptPhysician profile
Kary Vega
NPI 1720467848
$1,086.59
in general payments reported to CMS, 2019-2025
21 companies · $386 in 2025
The $386 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $87.59 · 2021: $121 · 2022: $53.48 · 2023: $195 · 2024: $52.99 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $633.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $133.64 | 2020-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $123.84 | 2025 | |
| Novo Nordisk INC | $122.42 | 2023 | Sogroya |
| Kowa Pharmaceuticals America, INC. | $120.95 | 2025 | Zoryve |
| Biogen, INC. | $119.51 | 2019 | |
| Glaxosmithkline, LLC. | $71.41 | 2020-2025 | Penmenvy, Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $58.19 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $50.93 | 2020-2022 | |
| Tris Pharma INC | $47.50 | 2019-2024 | Dyanavel Xr |
| Genentech USA, INC. | $44.78 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $28.21 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $22.77 | 2023 | Imcivree |
| Pfizer INC. | $21.22 | 2023 | |
| Alk-Abello, INC | $20.85 | 2025 | Ragwitek, Odactra, Grastek |
| Seqirus USA INC | $18.24 | 2025 | Flucelvax |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $16.40 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.97 | 2019 | |
| Verrica Pharmaceuticals INC. | $13.56 | 2023 | Ycanth |
| Shire North American Group INC | $12.37 | 2019 | |
| Phadia US INC. | $12.14 | 2022 | |
| Ironshore Pharmaceuticals INC. | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kary Vega listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.